Our findings suggest that elevated CDKN3 expression correlates with poorer OS, disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI), particularly in cancers such as ACC, BLCA, KIRC, KIRP, LGG, LIHC, MESO, PAAD, and UVM. Here, CDKN3 is linked to adrenal cortex carcinoma.